International Journal of Translational Research

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

International Journal of Translational Research-translation research of anti-cancer drugs
-Kun	Meng

Beijing Shenogen Pharma Group

Send an Email

Kun Meng


building B,
No.29 life science park road,
Beijing, 102206, China.

Research Interests:

translation research of anti-cancer drugs


  • Dr. Kun Meng is a co-founder, Chairman & CEO of Beijing Shenogen Pharma Group.
  • He has more than 15-year research experience in molecular biology, small molecule drug and pharmacology, as well as over 10-year experience of drug development and management in pharma industry.
  • Dr. Meng was CEO of a traditional Chinese medicine technology company and Chief Technical Officer of Jianxin Pharmaceuticals Co., Ltd.  
  • Dr. Meng received Ph.D. degree of Biochemistry from Chinese Academy of Sciences. He completed postdoctoral training in Harvard and Washington University School of Medicine, and he also received MPA degree from Kennedy School at Harvard.
  • Dr. Meng was elected to the National Thousand Talents, Beijing High-level Talents Organization and Beijing Scientific Leader Program.